Science Sphere

🧠 Researchers tested erythritol, a low-calorie sweetener found in many sugar-free and keto-friendly foods, on human cells that line blood vessels in the brain.

After exposure to levels similar to those found after one typical erythritol-sweetened drink, the cells showed signs of stress. They produced more damaging free radicals, less nitric oxide, and more endothelin-1 — a pattern that could make blood vessels less able to relax.

The cells also released less tissue plasminogen activator, a natural clot-clearing molecule. That matters because poor blood flow and impaired clot breakdown are linked to stroke risk.

This was a lab study on isolated cells, not proof that erythritol causes strokes in people. But it adds to growing evidence that frequent use of some sugar substitutes may deserve closer study.

📃 RESEARCH PAPER
📌 Berry et al., “The non-nutritive sweetener erythritol adversely affects brain microvascular endothelial cell function”, Journal of Applied Physiology (2025)

🫘 The compound nutritionists have warned about for decades may quietly be protecting your gut.

Phytic acid, abundant in beans, lentils, whole grains, nuts, and seeds, has long been dubbed an "anti-nutrient" because it binds minerals like iron, zinc, and calcium in the gut. A new study in Nature Communications suggests that label tells only half the story.
⁣
Researchers at the University of Nevada, Las Vegas worked out, at the molecular level, how phytic acid (also called InsP6) helps keep the intestinal lining sealed. They showed it directly switches on HDAC3, an enzyme inside intestinal cells that silences genes which would otherwise weaken the tight junctions holding gut cells together.
⁣
When HDAC3 cannot do its job, those junction-disrupting genes turn on, the barrier loosens, and bacterial molecules leak into the bloodstream, the signature of "leaky gut" and a hallmark of inflammatory bowel disease.
⁣
In mice missing the enzyme that produces InsP6, the intestinal barrier broke down and inflammation rose. When the researchers gave these mice oral InsP6, HDAC3 activity was restored and gut permeability dropped back toward normal levels. Strikingly, just 10 nanomolar of InsP6 was enough to selectively activate the enzyme.
⁣
The team cautions this is still preclinical. Whether ordinary plant-rich meals deliver enough usable InsP6 to the right tissues in humans is unknown, and the answer for patients with IBD will likely require purified, targeted formulations rather than diet alone.
⁣
📄 RESEARCH PAPER
📌 Chatterjee et al., "Phytic acid (InsP6) activates HDAC3 epigenetic axis to maintain intestinal barrier function", Nature Communications (2026)

💉 Ozempic may be doing more than melting fat. A new trial suggests it's slowing the body's biological clock.

Researchers at UC San Diego and partner institutions ran a post hoc analysis of a 32-week randomized, double-blind, placebo-controlled phase 2b trial of semaglutide, the active ingredient in Ozempic and Wegovy. The 84 participants were adults with HIV-associated lipohypertrophy, a group that tends to age biologically faster than the general population even when HIV is well controlled.

To measure aging, the team didn't look at wrinkles or weight. They read epigenetic clocks, tools that estimate biological age from DNA methylation, the chemical tags sitting on top of your genes that switch them on or off.

Compared to placebo, the semaglutide group showed a 9% slower "pace of aging" on the DunedinPACE clock. The PCGrimAge clock, which tracks mortality risk and age-related disease, fell by about 3.1 years, and PhenoAge dropped by nearly 4.9 years. Eleven different organ-system clocks moved in the same direction, with the strongest signals in inflammation, brain, and heart.

Why this might be happening: GLP-1 drugs cut chronic inflammation, reduce visceral fat, and lower metabolic stress. All three are now considered core drivers of biological aging, not just side effects of getting older. Emerging evidence also hints that these drugs may reprogram cells across multiple tissues.

Important caveats: this was a post hoc analysis (aging was not the original endpoint), the cohort was small and specific to people with HIV, and the readouts are molecular biomarkers, not lifespan or disease outcomes. Still, the authors call it the first randomized, placebo-controlled human evidence that a GLP-1 drug can slow aging biology.
⁣
📄 RESEARCH PAPER
📌 Corley et al., "Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy", Nature Communications (2026)

🌿 Peppermint oil may help lower blood pressure.

In a small randomized trial, researchers studied 40 adults with elevated blood pressure or stage 1 hypertension who were not taking blood pressure medication.

Participants took either 100 microliters of peppermint oil per day or a peppermint-flavored placebo for 20 days. By the end of the trial, systolic blood pressure was about 8.5 mmHg lower in the peppermint oil group compared with placebo. Resting heart rate also fell significantly.

Peppermint contains compounds such as menthol and flavonoids that may help blood vessels relax, but the study did not directly prove the mechanism.

This is promising, not definitive. The trial was short and small, so larger and longer studies are needed before peppermint oil can be recommended as a blood-pressure treatment.

📃 RESEARCH PAPER
📌 Sinclair et al., “Effects of peppermint (Mentha x piperita L.) oil on cardiometabolic outcomes in patients with pre- and stage 1 hypertension: A placebo randomized controlled trial”, PLOS One (2026)